Inhibitors of human immunodeficiency virus replication

A compound of Formula I

• where:
• R1 is N(R6)(R7);
• R2 is hydrogen, halo, or alkyl;
• R3 is alkyl, cycloalkyl, or Ar1;
• R4 is alkyl or haloalkyl;
• R5 is alkyl;
• R6 is hydrogen, alkyl, haloalkyl, (cycloalkyl)alkyl, (Ar2)alkyl, cycloalkyl, (alkyl)cycloalkyl, (Ar2)cycloalkyl, (alkyl)CO, (haloalkyl)CO, ((cycloalkyl)alkyl)CO, (Ar2)CO, ((Ar2)alkyl)CO, ((Ar2)alkyl)OCO, ((Ar2)alkyl)NHCO, or ((Ar2)alkyl)COCO;
• or R6 is ((trialkylsilyl)alkyl)OCO, (benzyloxy)alkylCO, (phenoxyalkyl)CO, (isoindolinedionyl)alkyl)CO, (((dialkyl)cycloalkoxy)alkyl)CO, (phenoxyalkyl)CO, or (dihalobenzodioxolyl)CO;
• R7 is hydrogen or alkyl;
• or N(R6)(R7) taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, or haloalkoxy;
• and
• Ar1 is phenyl, pyridinyl, indanyl, naphthyl, tetrahydronaphthalenyl, benzofuranyl, dihydrobenzofuranyl, benzodioxyl, chromanyl, isochromanyl, benzodioxanyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, dihydrobenzoxazinyl, indolyl, dihydroindolyl, benzthiazolyl, or benzothiazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxy, alkoxy, haloalkoxy, phenoxy, benzyloxy, thioalkyl, and acetamido;
• or Ar1 is
• Ar2 is phenyl, biphenyl, pyrazolyl, indolyl, or fluorenonyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy;
• or a pharmaceutically acceptable salt thereof.